Chimeric Therapeutics Share Price and Company Fundamentals



Price
$0.135
Change
-0.002 (-1.460%)
52 week
0.085 - 0.36

Last traded: Today at 5:53 AM

Chimeric Therapeutics Limited researches, develops, and commercializes cell therapies for cancer in Australia. The company develops CLTX CAR T cell therapy that is in Phase I clinical study for Glioblastoma; and CDH17 CAR T, which is in preclinical study for neuroendocrine tumours, as well as colorectal, pancreatic, and gastric cancer. It has a strategic partnership with OncoBay Clinical for the development program of CLTX CAR T. The company was incorporated in 2020 and is based in Carlton, Australia.

Key Metrics

PE ratio

-

PB ratio

3.35

Dividend yield

0.00%

Beta

-

Market cap

-

Enterprise value

-

Company profile

Primary activitiesChimeric is a biotechnology company developing a cancer cell therapy drug
Industry / SectorBiotechnology / Healthcare
Websitehttps://www.chimerictherapeutics.com
Mailing address62 Lygon Street Level 3 Carlton VIC 3053 Australia
Phone / Fax61 3 9824 5254 / 61 3 9822 7735
Share registryBOARDROOM PTY LIMITED

Dividends

More: Chimeric Therapeutics Dividend history, yield and payout ratio

Dividend yield

0.00%

Dividend amount

$0.00

Payout ratio

0.00%

Chimeric Therapeutics paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.CHM dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.

CHM's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Aug 2022, following are the company executives and directors listed on Chimeric Therapeutics.

NameTitleAgeTotal Pay
Ms. Jennifer ChowCEO, MD & Director1.23M
Dr. Li RenVP of Technical Operations
Mr. Eliot BourkChief Bus. Officer & Head of External Innovation
Mr. Kelly R. ThornburgVP & Head of Quality58
Mr. Jason B. Litten M.D.Chief Medical Officer47
Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBASec.60
Mr. Nathan Jong C.A.Company Sec.

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

0.00%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Chimeric Therapeutics is and its enterprise value is .

Companies similar to Chimeric Therapeutics (CHM)

Chimeric Therapeutics (ASX:CHM) Frequently Asked Questions

1. What is Chimeric Therapeutics's Stock Symbol?

Chimeric Therapeutics trades on ASX under the ticker symbol "CHM".

2. What is Chimeric Therapeutics's stock price today?

One share of CHM stock can currently be purchased for approximately $0.135.

3. How can I contact Chimeric Therapeutics?

Chimeric Therapeutics's mailing address is 62 Lygon Street Level 3 Carlton VIC 3053 Australia. The company can be reached via phone at 61 3 9824 5254.

4. What is Chimeric Therapeutics's official website?

The official website of Chimeric Therapeutics is https://www.chimerictherapeutics.com.

5. Which share registry manages Chimeric Therapeutics's stock?

Chimeric Therapeutics's stock is managed by BOARDROOM PTY LIMITED.